

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

207620Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION
CLINICAL STUDIES

NDA/BLA #: NDA 207-620
Supplement #:
Drug Name: LCZ696 (sacubitril/valsartan combination)
Indication(s): [REDACTED] (b) (4)
Applicant: Novartis
Date(s): 12/17/2014
Review Priority: Priority
Biometrics Division: DBI
Statistical Reviewer: John Lawrence, Ph D
Concurring Reviewers: Jim Hung, Ph D
Medical Division: Cardiorenal.
Clinical Team: Kimberly Smith MD, Tzu-Yun McDowell MD, Aliza Thompson MD
Project Manager: Alexis Childers
Keywords: active control, Cox regression, combination products

Table of Contents

EXECUTIVE SUMMARY	5
INTRODUCTION	6
1.1 OVERVIEW.....	6
1.2 DATA SOURCES	6
STATISTICAL EVALUATION	7
1.3 DATA AND ANALYSIS QUALITY	7
1.4 EVALUATION OF EFFICACY	7
1.4.1 <i>Study Design and Endpoints</i>	7
1.4.2 <i>Statistical Methodologies</i>	8
1.4.3 <i>Patient Disposition, Demographic and Baseline Characteristics</i>	9
1.4.4 <i>Results and Conclusions</i>	11
1.5 EVALUATION OF SAFETY	17
1.6 BENEFIT-RISK ASSESSMENT (OPTIONAL).....	17
FINDINGS IN SPECIAL/SUBGROUP POPULATIONS	17
1.7 GENDER, RACE, AGE, AND GEOGRAPHIC REGION	17
1.8 OTHER SPECIAL/SUBGROUP POPULATIONS	18
SUMMARY AND CONCLUSIONS	19
1.9 STATISTICAL ISSUES	19
1.10 COLLECTIVE EVIDENCE.....	19
1.11 CONCLUSIONS AND RECOMMENDATIONS	19
1.12 LABELING RECOMMENDATIONS (AS APPLICABLE).....	20

LIST OF TABLES

Table 1 List of all studies included in analysis	6
Table 2 Reasons for treatment discontinuation.....	10
Table 3 Patient demographic and baseline characteristics.....	11
Table 4 Adjudicated Primary Endpoint Analysis (CV death or HF hospitalization).....	12

LIST OF FIGURES

Figure 1 Weights for alpha relocation in the sequentially rejective multiple test procedure for the secondary hypotheses	9
Figure 2 Proportion of subjects included in primary analysis over time in the study.....	13
Figure 3 Kaplan-Meier estimates of event rates over time.	14
Figure 4 Log{-log(survival)} plot for primary endpoint (Time is shown on the log-scale on the x-axis, log(-log(estimated survival)) on the y-axis).	15
Figure 5 Kaplan-Meier estimates of all-cause mortality rates (secondary endpoint).....	16
Figure 6 High dose/warfarin results for subgroups defined by gender, race, age, and geographic region.	18

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.